Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Advances in Immunosuppression Research May Bring Transplant Patients Closer to “One Organ for Life”

Key Takeaway: Recent advancements in immunosuppression research are paving the way for transplant patients to potentially receive a single organ for life. This innovative approach aims to enhance the longevity and effectiveness of organ transplants, significantly improving patient outcomes. The focus on patient stories underscores the transformative impact of these developments in the field.
Price reaction · baseline $1.66 (2024-04-11 close) · hit after-hours · 6 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Research advancements may lead to improved transplant outcomes.
  • Potential for achieving 'One Organ for Life' concept.
  • Focus on patient stories highlights transformative impact.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the goal of the immunosuppression research?

The research aims to enable transplant patients to potentially receive one organ for life.

How might this research impact transplant outcomes?

Advancements could significantly improve the longevity and effectiveness of organ transplants.

What does 'One Organ for Life' mean?

'One Organ for Life' refers to the concept of achieving long-term success with a single organ transplant.

Are there patient stories related to this research?

Yes, the focus on patient stories highlights the transformative impact of these advancements.

Last updated: Apr 11, 2024